Sector News

Rumours resurface over Shire NPS bid

December 18, 2014
Life sciences
The rumour mill is running wild with renewed reports of a possible marriage between Dublin, Ireland-based Shire and US group NPS Pharmaceuticals.
 
As first reported by Bloomberg, citing sources close to the situation, Shire is considering making an offer for NPS should its flagship hormone replacement therapy Natpara receive a green light from US regulators.
 
Natpara (recombinant human parathyroid hormone) was filed with the US Food and Drug Administration in October for the treatment of hypoparathyroidism, and a decision is expected towards the end of January.
 
Though neither party has yet commented on the move, shares in NPS had leapt 20% and Shire’s stock was up nearly 3% in mid-afternoon trading on the Nasdaq on Wednesday.
 
Interestingly, these are not the first whispers of such a deal; back in June various media reports were suggesting that Shire is planning to make an offer in the region of $4 billion for NPS, though these soon were quashed by the US group.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach